PREVENT Preclinical Efficacy & Endpoint Biomarkers

Award Notice Posted

Solicitation number
75N91023R00024
Agency
Awarded
to University Of Oklahoma
Set-aside
No set-aside

Opportunity facts

Contract number
75N91024D00005 Federal IDV award

Notice details come from SAM.gov. Updated .

About this opportunity

The University of Oklahoma was awarded a Preclinical Efficacy & Intermediate Endpoint Biomarkers IDIQ contract by the National Cancer Institute, part of the National Institutes of Health within the Department of Health and Human Services. This contract, valued at $149,995,000, will support the PREVENT Cancer Preclinical Drug Development Program through the provision of preclinical efficacy and endpoint biomarkers services on an indefinite delivery/indefinite quantity basis. The contract was awarded on January 24, 2024 with no set-aside designation specified.

Notice text

Preclinical Efficacy & Intermediate Endpoint Biomarkers IDIQ contract in support of the PREVENT Cancer Preclinical Drug Development Program Awarded contract 75N91024D00005 to UNIVERSITY OF OKLAHOMA for 149995000 on 2024-01-24.

Notice history

6 of 13 notices listed here. See the rest on GovTribe.

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity

GovTribe for Federal Contractors